Molecular Subtype
Triple-Negative Invasive Breast Lobular Carcinoma
CI-CAN-00008568Explore in graph →
1 active trials
- NCIt
- C223369
Loading cancer entity…
Molecular Subtype
CI-CAN-00008568Explore in graph →
Clinical trials
1 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (0)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07229417 | A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma | recruiting | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 29, 2026source: clinicaltrials